Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma
British Journal of Haematology · 2026-07 · 209 (1) · 189-196
DOI: 10.1111/bjh.70502 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 21.04.2026. Verfasst von Sarah Dingli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Earl E. Bakken Medical Devices Center, Department of Mechanical Engineering, College of Science and Engineering, University of Minnesota, Twin Cities…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Receptors, Chimeric Antigen, Lymphoma, Non-Hodgkin. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Centurion Fund through the Department of Development at Mayo Clinic.
Abstract (Originalsprache)
Chimeric antigen receptor T cells directed against CD‐19 are highly effective therapies for various subtypes of B‐cell non‐Hodgkin lymphoma (NHL). We have studied the impact of patient‐specific lymphocyte growth kinetics after lymphoid depletion chemotherapy on both long‐term outcomes and toxicity in patients with diffuse large B‐cell non‐Hodgkin lymphoma (DLBCL). The growth of the lymphocyte populations early after chimeric antigen receptor T‐cell (CAR‐T) therapy is well described by an exponential function and the growth rate of the cells appears to be one of the most critical determinants of overall survival in these patients. The maximum lymphocyte peak and the area under curve for lymphocytes within the first 4 weeks after CAR‐T therapy had no impact on survival. Receiver operator characteristic analysis determined that a replication rate ≥0.3876/day is associated with superior rates of complete response and durable responses. This threshold is associated with higher grades of cytokine release syndrome and the need for tocilizumab. However, patients with this threshold have a median overall survival of 3.04 years compared to 1.035 years for patients with slower lymphocyte replication ( p = 0.0206). The major determinant of depth of response and durability of response to CAR‐T in NHL is the speed of lymphocyte expansion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Earl E. Bakken Medical Devices Center, Department of Mechanical Engineering, College of Science and Engineering, University of Minnesota, Twin Cities, Minnesota, USA.
- Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Sarah Dingli, Paul Rothweiler, Albert Atallah-Yunes, Stephen M Ansell, Urshila Durani, Yucai Wang, Arthur G Erdman, David Dingli
Förderung
- Centurion Fund through the Department of Development at Mayo Clinic
Zitieren
APA
Dingli, S., Rothweiler, P., Corraes, A. M. S., Atallah-Yunes, A., Ansell, S. M., Bennani, N. N., Durani, U., Johnston, P. B., Khurana, A., Paludo, J., Bisneto, J. C. V., Wang, Y., Lin, Y., Erdman, A. G., & Dingli, D. (2026). Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma. British Journal of Haematology, 209(1), 189-196. https://doi.org/10.1111/bjh.70502
Vancouver
Dingli S, Rothweiler P, Corraes AMS, Atallah-Yunes A, Ansell SM, Bennani NN, et al. Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma. British Journal of Haematology. 2026;209(1):189-196. doi:10.1111/bjh.70502
BibTeX
@article{Dingli2026,
author = {Dingli, Sarah and Rothweiler, Paul and Corraes, Andre De Menezes Silva and Atallah-Yunes, Albert and Ansell, Stephen M and Bennani, N Nora and Durani, Urshila and Johnston, Patrick B and Khurana, Arushi and Paludo, Jonas and Bisneto, J C Villasboas and Wang, Yucai and Lin, Yi and Erdman, Arthur G and Dingli, David},
title = {Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {1},
pages = {189--196},
doi = {10.1111/bjh.70502}
}
EUVIMED